OMER earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E 7.57. Updated 2026-07-23.
Omeros (OMER) Research Hub
Omeros (OMER) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 18.28 USD (-5.72%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 7.57, market cap 0.70B. This hub links to the full technical, earnings and options research available for OMER.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 18.28 USD (-5.72%) |
| 52-week range | 7.39 USD – 19.65 USD |
| Trend regime | Range |
| 14-day RSI | 76 (Overbought) |
| Trailing P/E | 7.57 |
| Market cap | 0.70B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for OMER
Covered Call on OMER: how it works, illustrative setup around the real 18.28 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on OMER: how it works, illustrative setup around the real 18.28 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on OMER: how it works, illustrative setup around the real 18.28 USD price, max profit/loss, breakeven and when to use it. Educational.
OMER technical analysis: range, last 18.28 USD, RSI 76, 52w range 7.39 USD–19.65 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is OMER in?
Omeros (OMER) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is OMER in an uptrend or downtrend?
As of 2026-09-11, OMER is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is OMER's trailing P/E ratio?
OMER's trailing P/E is 7.57, with a market cap of 0.70B. See the earnings research page for full valuation detail.
When does OMER next report earnings?
OMER is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.27 USD.